OR WAIT null SECS
February 02, 2026
Article
Catch up with major FDA decisions, key guidelines updates, and more.
January 12, 2026
Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.
January 09, 2026
The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.
January 06, 2026
Catch up with major FDA decisions, critical conference news, and more.
December 19, 2025
The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.
December 04, 2025
December 03, 2025
Video
Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.
November 28, 2025
Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.
November 14, 2025
Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.
November 04, 2025
Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.
